Daqi Xu

748 citations
14 papers · 361 indexed · h-index 8
Topics
T-cell and B-cell Immunology (5 papers)Immune Cell Function and Interaction (5 papers)Diabetes and associated disorders (2 papers)
Partner nations
United StatesChinaFrance

In The Last Decade

Daqi Xu

14 papers receiving 358 citations

Peers

Daqi Xu
Comparison fields: 5 of 73
  • Immunology 205
  • Molecular Biology 132
  • Oncology 71
  • Genetics 35
  • Cancer Research 26
Replace Philipp Stüve with:
Philipp Stüve Germany
Yoshiyuki Hizukuri Japan
Katherine A. Lundeen United States
Chuanping Si China
Christine Rentzsch Germany
Pichugin Av Russia
Takayuki Yoshizaki Japan
Jonathan Werner United States
Marine Oberkampf France
Carlos Plaza‐Sirvent Germany
Daqi Xu relative to Philipp Stüve Germany Philipp Stüve's profile →
Citations per field
00.5×1.5×
Philipp Stüve · 1×
Citations per year

Countries citing papers authored by Daqi Xu

Since Specialization
Citations

This map shows the geographic impact of Daqi Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daqi Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daqi Xu more than expected).

Fields of papers citing papers by Daqi Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daqi Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daqi Xu. The network helps show where Daqi Xu may publish in the future.

Co-authorship network of co-authors of Daqi Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Daqi Xu. A scholar is included among the top collaborators of Daqi Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daqi Xu. Daqi Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
#WorkIndexed citations
1 5
2 2
3 2
4 1
5 17
6 57
7 58
8 69
9 64
10 21
11 6
12 39
13
[Tetramethylpyrazine accelerated spinal cord repair through regulation of caspase-3 and neurofilament protein expression: an acute spinal cord injury model in rats].
6
14 14

About Daqi Xu

Daqi Xu is a scholar working on Immunology, Biochemistry and Biotechnology, having authored 14 papers that have together received 361 indexed citations. Recurring topics across this work include T-cell and B-cell Immunology (5 papers), Immune Cell Function and Interaction (5 papers) and Diabetes and associated disorders (2 papers). The work is most often cited by research in Immunology (205 citations), Biochemistry (20 citations) and Oncology (71 citations). Daqi Xu has collaborated with scholars based in United States, China and France. Frequent co-authors include Jeffrey A. Bluestone, Eleonora Trotta, Brent S. McKenzie, M Matsumoto, Brian S. Sheridan, Kamal M. Khanna, Leigh Maher, Alexandre P. Bénéchet, Thomas T. Murooka and Thorsten R. Mempel. Their work appears in journals such as Proceedings of the National Academy of Sciences, Molecular Cell and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026